Outcomes 2019 - Baylor Scott & White Heart and Vascular Hospital BSWHHVH_646_2019 Outcomes JOOMAG MOD | Page 43

Baylor Dallas performs its 500th LVAD implantation
As advances in heart failure treatment continue, Baylor University Medical
Center remains at the forefront and is still one of the largest programs in Texas.
In fiscal year 2019, surgeons on the medical staff performed 50 heart
transplants and implanted a record 68 LVADs (left ventricular assist device).
Dan Meyer, MD, a physician on the medical staff at Baylor University Medical
Center, implanted the first LVAD at Baylor Dallas in 1996, and recently implanted
the 500th LVAD, making Baylor Dallas the first hospital in North Texas to reach
this milestone. Currently Dr. Meyer is the surgical chief of heart transplant and
mechanical circulatory support at Baylor University Medical Center.
Baylor University Medical Center is one of the busiest programs in
the nation for extracorporeal membrane oxygenation, or ECMO. The
partnered approach between cardiology and vascular surgery allows
access for the device to be administered by fellowship-trained vascular
surgeons who specialize in vascular cutdown. This increases the quality
of care to these acute patients as recognized by the Extracorporeal Life
Support Organization (ELSO) who awarded Baylor University Medical
Center with the 2018 ELSO Award for Excellence in Life Support – Gold
Level. The award recognized extracorporeal life support programs
worldwide that distinguish themselves by having processes, procedures
and systems in place that promote excellence and exceptional care in
providing ECMO to their patients.
Baylor University Medical Center has expanded its capabilities and quality
by helping spearhead a collaborative project with Baylor Scott & White’s
three other hospitals offering the specialized technology. A streamlined
ECMO transfer program, available 24/7, is now available to rapidly bring
patients to the closest Baylor Scott & White center offering ECMO. Timely
action for these critically ill patients is supported through collaborations
with regional hospitals for patient transports and with CareFlite ® for
helicopter and fixed-wing capabilities.
Advanced heart failure-related research
Baylor Dallas will serve as one of three trial sites to evaluate the safety
and efficacy of a continuous flow left ventricular assist system (LVAS) for
patients with advanced heart failure for use as a bridge to transplantation
in candidates listed for cardiac transplant. In another study, Baylor Dallas
will evaluate whether a new total artificial heart can serve as a bridge to
transplant for transplant-eligible patients at imminent risk of death from
biventricular failure without experiencing permanent disabling, stroke-
related deficits. The team is also participating in the EVAHEART LVAD trial,
a novel LVAD under a new clinical trial which may offer a decreased number
of bleeding complications than present with the current technologies.
Principal Investigator for EVAHEART: Dan Meyer, MD.
For more information and a complete list of updated clinical trials, visit
BaylorHeartHospital.com/ClinicalTrials. For more information on the
Advanced Heart Failure program or to refer a patient, call 214.820.6856.
ECMO support
volume
Calendar
year Total ECMO
cases
2018 112
2017 114
2016 118
Total ECMO indications*
count for Baylor Dallas
(CY18)
Pulmonary
52
ECPR
22
Cardiac
36
Extracorporeal life support
43
Post D/C ECMO survival
at 30 days:
98%
Count of ECMO patients
alive at 30 days/count of
patients discharged at
Baylor Dallas* (CY18):
42/43
ECMO Transfers (CY18):
24